We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

49 hedge funds and large institutions have $30.2M invested in Axsome Therapeutics in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,200% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 1

20% more funds holding

Funds holding: 41 → 49 (+8)

1.66% more ownership

Funds ownership: 32.21% → 33.86% (+1.7%)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

27% less capital invested

Capital invested by funds: $41.6M → $30.2M (-$11.4M)

Holders
49
Holders Change
+8
Holders Change %
+19.51%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
12
Reduced
12
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RA
Royce & Associates
New York
+$4.21M
2
BlackRock
BlackRock
New York
+$2.35M
3
SFM
Sphera Funds Management
Israel
+$1.92M
4
NC
Nexthera Capital
New York
+$1.91M
5
OPPM
Opus Point Partners Management
New York
+$1.28M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.7M
2
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.69M
3
Morgan Stanley
Morgan Stanley
New York
-$157K
4
JP Morgan Chase
JP Morgan Chase
New York
-$39.9K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$39.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$67K -$157K -32,855 -66%
TA
27
Teachers Advisors
New York
$66K – – –
JMFC
28
J.M. Forbes & Co
Massachusetts
$59K – – –
RhumbLine Advisers
29
RhumbLine Advisers
Massachusetts
$53K +$65.4K +13,688 New
VKH
30
Virtu KCG Holdings
New York
$49K +$60.4K +12,631 New
SSB
31
Sandy Spring Bank
Maryland
$34K – – –
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$33K +$5 +1 +0%
Barclays
33
Barclays
United Kingdom
$30K +$36.9K +7,718 +5,553%
AIG
34
American International Group
New York
$27K +$2.14K +448 +7%
NFA
35
Nationwide Fund Advisors
Ohio
$25K – – –
Deutsche Bank
36
Deutsche Bank
Germany
$22K -$5.95K -1,245 -18%
TRCT
37
Tower Research Capital (TRC)
New York
$16K +$19.9K +4,170 New
SO
38
STRS Ohio
Ohio
$14K – – –
Bank of America
39
Bank of America
North Carolina
$13K +$8.38K +1,754 +115%
Wells Fargo
40
Wells Fargo
California
$9K – – –
Legal & General Group
41
Legal & General Group
United Kingdom
$5K – – –
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$3K -$301 -63 -8%
AIP
43
Ameritas Investment Partners
Nebraska
$3K +$4.14K +866 New
MAM
44
Meeder Asset Management
Ohio
$2K -$358 -75 -13%
LTFS
45
Ladenburg Thalmann Financial Services
Florida
$2K – – –
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K – – –
UBS Group
47
UBS Group
Switzerland
$1K -$7.08K -1,481 -85%
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$269 -$736 -154 -69%
LOAMU
49
Lombard Odier Asset Management (USA)
New York
– -$1.69M -250,000 Closed
Citigroup
50
Citigroup
New York
– -$16.3K -3,406 -99%
1
2

AXSM Hedge Fund Activity: Q1 2017 in Review

49 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2017, worth a combined $30.2M — down 27% from $41.6M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AXSM positions and 1 closed out — a net gain of 12 holders — while 12 added to existing stakes and 12 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $4.21M. The largest seller was Fidelity Investments, cutting an estimated $2.7M.

  • 49 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2017, up from 41 in Q4 2016.
  • Funds reported $30.2M of Axsome Therapeutics stock for Q1 2017, down 27% quarter-over-quarter.
  • 13 funds opened new Axsome Therapeutics positions in Q1 2017 and 1 closed out, a net change of +12 holders.
  • The largest Axsome Therapeutics buyer in Q1 2017 was Royce & Associates, an estimated $4.21M added.
  • The largest Axsome Therapeutics seller in Q1 2017 was Fidelity Investments, an estimated $2.7M sold.

Based on aggregated 13F filings for Q1 2017.